Shandong Buchang Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chao Zhao

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentage	n/a
CEO tenure	23.8yrs
CEO ownership	n/a
Management average tenure	14.8yrs
Board average tenure	12.7yrs

Recent management updates

Recent updates

CEO

Chao Zhao (57 yo)

23.8yrs

Tenure

CN¥2,439,600

Compensation

Mr. Chao Zhao serves as the President and Director of Shandong Buchang Pharmaceutical Co., Ltd. since 2001 and served as its General Manager since 2001. Mr. Zhao serves as Executive Director and General Ma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chao Zhao	President & Director	23.8yrs	CN¥2.44m	no data
Yi Min Wang	Executive VP & Vice Chairman	12.7yrs	CN¥2.16m	no data
Ren Hui Xue	VP of Marketing & Director	14.8yrs	CN¥2.12m	no data
Xifang Wang	Chief Engineer	7.7yrs	CN¥1.11m	no data
Xiao Ping Pu	VP of Securities	13.8yrs	CN¥1.40m	no data
Zhao Buchang	Founder	no data	no data	no data
Bao Cai Wang	CFO & Director	14.8yrs	CN¥931.30k	no data
Kai Cheng	Accounting Supervisor	no data	no data	no data
Haiqin Wu	Chairman of the Academic Committee	no data	no data	no data
Wei Zhao	Vice President of Procument	no data	no data	no data

14.8yrs

Average Tenure

62yo

Average Age

Experienced Management: 603858's management team is seasoned and experienced (14.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chao Zhao	President & Director	23.8yrs	CN¥2.44m	no data
Yi Min Wang	Executive VP & Vice Chairman	12.7yrs	CN¥2.16m	no data
Ren Hui Xue	VP of Marketing & Director	12.7yrs	CN¥2.12m	no data
Xiao Ping Pu	VP of Securities	12.7yrs	CN¥1.40m	no data
Bao Cai Wang	CFO & Director	12.7yrs	CN¥931.30k	no data
Yu Gao	Director	12.7yrs	CN¥190.50k	no data
Tao Zhao	Chairman of the Board of Directors	23.8yrs	no data	53.83% CN¥ 9.4b
Jing Zhao	Vice Chairman of the Board	12.7yrs	CN¥1.45m	no data
Ya Feng Wang	Director	12.7yrs	CN¥190.50k	no data
Chun Yi Li	Director	12.7yrs	CN¥190.50k	no data
Hua Cheng	Independent Director	3.4yrs	CN¥190.50k	no data
Ming Geng Wang	Chairman of the Supervisory Board	12.7yrs	no data	no data

12.7yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 603858's board of directors are seasoned and experienced ( 12.7 years average tenure).

Shandong Buchang Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Shandong Buchang Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.076 (vs CN¥0.16 in 3Q 2023)

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Dividend of CN¥0.13 announced

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shandong Buchang Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.41 in 1Q 2023)

Now 26% undervalued

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Now 22% undervalued

Now 23% undervalued after recent price drop

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) announces an Equity Buyback for CNY 360 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.41 in 3Q 2022)

Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858),Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: CN¥1.50 loss per share (vs CN¥1.17 profit in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.49 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.37 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.45 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.54 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.28 in 1Q 2020)

New 90-day low: CN¥20.39

New 90-day low: CN¥21.77

New 90-day low: CN¥23.46

New 90-day low: CN¥23.63

New 90-day low: CN¥24.21

Third quarter earnings released

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low: CN¥24.81

First half earnings released

First half earnings released

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age